Dapsone has indications for several conditions, both dermatologic and non-dermatologic. The FDA-approved indications are leprosy and dermatitis herpetiformis.

The non-FDA approved indications include the following

- Linear IgA bullous dermatosis, chronic bullous dermatosis of childhood, bullous systemic lupus erythematosus, and erythema elevatum diutinum

- Autoimmune bullous dermatoses such as bullous pemphigoid, cicatricial pemphigoid, IgA pemphigus, subcorneal pustular dermatosis, pemphigus vulgaris, pemphigus foliaceous, and epidermolysis bullosa acquisita

- Vasculitic dermatoses such as leukocytoclastic vasculitis and urticarial vasculitis

- Neutrophilic dermatoses such as Sweet syndrome, pyoderma gangrenosum, and Behcet syndrome

- Other dermatoses such as subacute cutaneous lupus erythematosus, relapsing polychondritis, granuloma annulare, loxoscelism, granuloma faciale, rosacea, panniculitis, pustular psoriasis, nodulocystic acne, and rhinosporidiosis

Non-dermatologic indications are malaria and Pneumocystis (carinii) jiroveci prophylaxis and treatment.